<DOC>
	<DOC>NCT00844324</DOC>
	<brief_summary>This study is designed as a Phase-I, 2-period, cross-over, randomised, open-label, single centre study to determine bioequivalence of a single 32 mg dose of the proposed commercial oral suspension of candesartan cilexetil (1 mg/mL) and a single 32 mg dose of the candesartan cilexetil oral suspension (1.6 mg/mL) used in the paediatric program.</brief_summary>
	<brief_title>Bioequivalence Study in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Provision of informed consent prior to any study specific procedures Body mass index (BMI) 1927 kg/m2 calculated from height and weight at the Screening visit Clinically normal physical findings including ECG and safety laboratory values at the Screening visit and on Day 1 of each treatment period, including negative results for drugsofabuse, alcohol, Hepatitis B, Hepatitis C and HIV. History of significant mental, cardiac, renal, hepatic or significant gastrointestinal disease (that may affect the rate and extent of absorption of the IP), as judged by the Investigator Any condition which could modify the absorption of the IPs Previous randomisation of treatment in the present study History or symptoms and signs of ongoing severe allergic disease/hypersensitivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Candesartan</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>